Short-Acting Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Apidra, Novolog, Humalog, Novolin, Others), By Application (Type 1 Diabetes, Type 2 Diabetes), By Region & Competition, 2021-2031F

January 2026 | 185 pages | ID: S5B74D73F1A5EN
TechSci Research

Abstracts

The Global Short-Acting Insulin Market is projected to expand from USD 8.16 billion in 2025 to USD 10.49 billion by 2031, achieving a compound annual growth rate of 4.27%. This therapeutic category functions as a vital prandial hormone replacement, designed to regulate blood glucose levels by mimicking the body's natural insulin release immediately following food ingestion. The primary catalyst for this growth is the escalating global incidence of diabetes mellitus alongside rising obesity rates, both of which necessitate effective glycemic control to prevent severe health complications. According to the International Diabetes Federation, approximately 589 million adults aged 20 to 79 were living with diabetes worldwide in 2024, creating an urgent and sustained demand for reliable therapeutic interventions across an expanding patient demographic.

However, market expansion is significantly impeded by the high costs associated with insulin manufacturing and the stringent regulatory requirements necessary for product approval. These economic and legislative hurdles often create disparities in access and affordability, particularly within low-to-middle-income regions where healthcare resources are limited. Such challenges effectively restrict the widespread adoption of these critical treatments and negatively impact patient adherence rates in key growth markets, preventing the sector from fully capitalizing on the rising global need for diabetes management solutions.

Market Driver

The introduction and adoption of cost-effective biosimilar insulins act as a transformative driver for the Global Short-Acting Insulin Market, particularly as patents for originator biologics expire. This transition fosters intense price competition and broadens patient access in both developed nations and price-sensitive emerging economies, alleviating financial pressure on healthcare systems while accelerating volume uptake among populations previously constrained by cost barriers. The success of this shift is highlighted by Biocon Biologics, which reported a 19% year-over-year revenue increase in its biosimilars portfolio, including key insulin assets, in its October 2024 earnings update, underscoring the rapid market penetration and commercial viability of these affordable therapeutic alternatives.

Concurrently, advancements in insulin delivery devices and technology are further propelling market growth by enhancing the precision and convenience of administration. The integration of smart insulin pens and automated insulin delivery (AID) systems improves patient adherence and glycemic outcomes, thereby securing consistent demand for compatible fast-acting insulin formulations. The impact of this technological synergy is evident in Insulet Corporation?s November 2024 financial results, where revenue surged by 25.7% to $543.9 million driven largely by tubeless pump adoption. Additionally, Novo Nordisk reported a 10% growth in insulin product sales during the first nine months of 2024, reflecting sustained global usage of these essential therapeutics.

Market Challenge

A substantial restraint on the global short-acting insulin market is the prohibitive cost of manufacturing combined with stringent regulatory requirements. Developing insulin products involves complex, capital-intensive biological processes that must strictly adhere to safety protocols and quality standards established by international health authorities. These rigorous compliance obligations necessitate significant investment in specialized facilities and technical expertise, creating a high production price floor that prevents manufacturers from aggressively lowering costs to capture volume in price-sensitive developing regions without compromising their financial sustainability.

Consequently, these economic and legislative barriers directly limit patient access and restrict the market?s revenue potential in critical growth territories. High retail prices often exceed the financial capabilities of individuals and healthcare systems in low-to-middle-income countries, leading to suboptimal treatment uptake. According to the World Health Organization, more than 50% of people living with diabetes worldwide were not receiving treatment in 2024, a significant gap largely attributed to the lack of access to affordable insulin and essential care in lower-income settings. This widespread affordability crisis reduces patient adherence and prevents the market from fully serving the expanding global patient population.

Market Trends

Advancements in inhalable short-acting insulin solutions are driving a significant market shift by offering a non-invasive alternative to traditional prandial injections. This trend focuses on enhancing patient quality of life and compliance through pulmonary delivery systems that utilize specialized particle engineering to provide ultra-rapid absorption kinetics comparable to physiological insulin secretion. The commercial appeal of such innovative formulations is reflected in MannKind Corporation?s November 2024 financial results, which reported a 12% year-over-year revenue increase for its flagship product, Afrezza, reaching $15 million and signaling a persistent demand for needle-free therapeutic options among the diabetes community.

Simultaneously, the transition toward ultra-rapid acting insulin analogs represents a critical evolution in glycemic management, aiming to close the time lag between administration and the onset of action found in standard rapid-acting products. By reformulating existing molecules with novel excipients to accelerate absorption, pharmaceutical developers allow patients to administer dosage closer to mealtime for improved postprandial glucose control. This product class continues to maintain a strong footprint in global portfolios, as evidenced by Novo Nordisk?s report of 394 million Danish kroner in sales for its ultra-rapid formulation Fiasp during the third quarter of 2024, underscoring the sustained relevance of pharmacokinetically optimized insulins in modern treatment algorithms.

Key Market Players

• Novo Nordisk AS
• Sanofi SA
• Eli Lilly & Co
• Biocon Ltd
• Wockhardt Ltd
• Boehringer Ingelheim International GmbH
• Julphar Pharma Inc
• United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co. Ltd.

Report Scope

In this report, the Global Short-Acting Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Short-Acting Insulin Market, By Drugs
• Apidra
• Novolog
• Humalog
• Novolin
• Others
• Short-Acting Insulin Market, By Application
• Type 1 Diabetes
• Type 2 Diabetes
• Short-Acting Insulin Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short-Acting Insulin Market.

Available Customizations:

Global Short-Acting Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL SHORT-ACTING INSULIN MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Drugs (Apidra, Novolog, Humalog, Novolin, Others)
  5.2.2. By Application (Type 1 Diabetes, Type 2 Diabetes)
  5.2.3. By Region
  5.2.4. By Company (2025)
5.3. Market Map

6. NORTH AMERICA SHORT-ACTING INSULIN MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Drugs
  6.2.2. By Application
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Short-Acting Insulin Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Drugs
      6.3.1.2.2. By Application
  6.3.2. Canada Short-Acting Insulin Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Drugs
      6.3.2.2.2. By Application
  6.3.3. Mexico Short-Acting Insulin Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Drugs
      6.3.3.2.2. By Application

7. EUROPE SHORT-ACTING INSULIN MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Drugs
  7.2.2. By Application
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Short-Acting Insulin Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Drugs
      7.3.1.2.2. By Application
  7.3.2. France Short-Acting Insulin Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Drugs
      7.3.2.2.2. By Application
  7.3.3. United Kingdom Short-Acting Insulin Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Drugs
      7.3.3.2.2. By Application
  7.3.4. Italy Short-Acting Insulin Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Drugs
      7.3.4.2.2. By Application
  7.3.5. Spain Short-Acting Insulin Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Drugs
      7.3.5.2.2. By Application

8. ASIA PACIFIC SHORT-ACTING INSULIN MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drugs
  8.2.2. By Application
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Short-Acting Insulin Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Drugs
      8.3.1.2.2. By Application
  8.3.2. India Short-Acting Insulin Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Drugs
      8.3.2.2.2. By Application
  8.3.3. Japan Short-Acting Insulin Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Drugs
      8.3.3.2.2. By Application
  8.3.4. South Korea Short-Acting Insulin Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Drugs
      8.3.4.2.2. By Application
  8.3.5. Australia Short-Acting Insulin Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Drugs
      8.3.5.2.2. By Application

9. MIDDLE EAST & AFRICA SHORT-ACTING INSULIN MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drugs
  9.2.2. By Application
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Short-Acting Insulin Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drugs
      9.3.1.2.2. By Application
  9.3.2. UAE Short-Acting Insulin Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drugs
      9.3.2.2.2. By Application
  9.3.3. South Africa Short-Acting Insulin Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drugs
      9.3.3.2.2. By Application

10. SOUTH AMERICA SHORT-ACTING INSULIN MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Drugs
  10.2.2. By Application
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Short-Acting Insulin Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Drugs
      10.3.1.2.2. By Application
  10.3.2. Colombia Short-Acting Insulin Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Drugs
      10.3.2.2.2. By Application
  10.3.3. Argentina Short-Acting Insulin Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Drugs
      10.3.3.2.2. By Application

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL SHORT-ACTING INSULIN MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Novo Nordisk AS
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Sanofi SA
15.3. Eli Lilly & Co
15.4. Biocon Ltd
15.5. Wockhardt Ltd
15.6. Boehringer Ingelheim International GmbH
15.7. Julphar Pharma Inc
15.8. United Laboratories International Holdings Limited
15.9. Tonghua Dongbao Pharmaceutical Co. Ltd.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER